EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

2022.10.13

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

2022.08.15

EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”

2022.07.15

Date

Title

2019-08-21

Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List

2019-08-12

Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million

2019-08-02

Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment

2019-07-19

Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea

2019-05-15

Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index

2019-04-29

Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

2019-03-12

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

2019-01-10

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT